March 30, 2022. ALS is a devastating disease and all of us want better treatments to be available as soon as possible. But NCHR agrees with FDA that “The secondary endpoint results are not compelling or supportive of the primary endpoint.”
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comments On Transitional Standards for Milk, Whole Grains, and Sodium
March 24, 2022. Nutrition standards that ensure that children receive healthy food alternatives in their school meals are of utmost importance. For this reason, we agree that USDA’s proposed transition standards, which will reduce sodium and increase whole grains, are a much-needed improvement to Child Nutrition Programs.
Read More »NCHR Comments on Statin Use for the Primary Prevention of Cardiovascular Disease
March 21, 2022. We generally agree with the USPSTF’s recommendations for preventive statin use, but suggest several improvements. For example, the studies included in the review varied greatly in the types of patients studied and the outcomes measured, and it seems premature to assume the risks are small, especially since even rare risks can be very serious for some patients. We thus urge the USPSTF to recommend that physicians emphasize other strategies to lower cholesterol, such as changes to lifestyle and diet.
Read More »NCHR Comments on AHRQ’s Review on Schedule of Visits and Televisits for Routine Antenatal Care
March 15, 2022. We agree with the review that the overall assessment of the available evidence is inconclusive regarding the adequacy of a reduced number of antenatal visits or replacing some routine antenatal visits with telehealth appointments.
Read More »NCHR Comments on USPSTF’s Draft Recommendation on Screening for Syphilis Infection in Nonpregnant Adolescents and Adults
March 14, 2022. We support the reaffirmation of the previous “A” recommendation of syphilis screening in persons who are at increased risk for infection. However, we urge USPSTF to provide as much guidance as possible to ensure that healthcare providers do not base their decisions on personal or widely held stereotypes pertaining to age, race, ethnicity, social class, or appearance.
Read More »